Blue Trust Inc. Has $50,000 Holdings in ADMA Biologics Inc $ADMA

Blue Trust Inc. grew its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 53.6% during the second quarter, Holdings Channel.com reports. The firm owned 2,762 shares of the biotechnology company’s stock after acquiring an additional 964 shares during the quarter. Blue Trust Inc.’s holdings in ADMA Biologics were worth $50,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ADMA. Farther Finance Advisors LLC raised its holdings in shares of ADMA Biologics by 1,149.1% in the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 2,505 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of ADMA Biologics by 251.6% in the first quarter. GAMMA Investing LLC now owns 6,589 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 4,715 shares during the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of ADMA Biologics by 7.4% in the first quarter. Janney Montgomery Scott LLC now owns 70,991 shares of the biotechnology company’s stock valued at $1,408,000 after purchasing an additional 4,865 shares during the last quarter. Envestnet Portfolio Solutions Inc. acquired a new stake in shares of ADMA Biologics in the first quarter valued at approximately $240,000. Finally, PFG Investments LLC raised its holdings in shares of ADMA Biologics by 0.6% in the first quarter. PFG Investments LLC now owns 222,809 shares of the biotechnology company’s stock valued at $4,421,000 after purchasing an additional 1,301 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “buy (b-)” rating on shares of ADMA Biologics in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $27.67.

ADMA Biologics Stock Performance

NASDAQ ADMA opened at $14.36 on Friday. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. The firm’s fifty day moving average price is $16.00 and its two-hundred day moving average price is $18.36. ADMA Biologics Inc has a 1 year low of $13.50 and a 1 year high of $25.67. The firm has a market capitalization of $3.43 billion, a P/E ratio of 16.70 and a beta of 0.47.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm had revenue of $121.98 million for the quarter, compared to the consensus estimate of $121.77 million. During the same period in the previous year, the company earned $0.13 earnings per share. The company’s quarterly revenue was up 13.8% on a year-over-year basis. As a group, research analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.